A Phase 3 interventional study of Dupilumab in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 15 sites in 3 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 50th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 37th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 5 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT06931405Blueprint Medicines CorporationStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details included: Screening: 2 to 4 weeks; The treatment duration was 24 weeks; Follow-up period: 12 weeks; The study duration was 38 to 40 weeks (including screening and follow-up); The number of study visits was 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants were excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age
Drug: Dupilumab
Injection solution Subcutaneous
Also known as: Dupixent
Serum Concentration of Dupilumab at Weeks 12 and 24
Blood samples were collected at specified timepoints to obtain dupilumab concentration.
Time frame: Weeks 12 and 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
Time frame: From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks
Number of Participants With Anti-drug Antibodies (ADAs) to Dupilumab
Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.
Time frame: From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks
Change From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24
The C-DLQI assesses impact of skin disease on children's health-related quality of life (HRQoL) over the previous week, contains 10 questions related to symptoms feelings associated with disease, impact of disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease. All questions were scored on 4-point Likert scale:0 (not at all),1 (a little),2 (a lot),3 (very much). Total C-DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24
The IDQOL questionnaire is completed by child's caregiver/guardian with a recall period of 7 days;consists of 10 questions focusing on life quality index (LQI) scored on 4-point Likert scale. An additional question on dermatitis severity is scored on a 5-point Likert scale (0 \[none\] to 4 \[extremely severe\]); it is not considered for calculating total IDQOL. For LQI, score ranges are as follows: Questions 1, 5 to 10: 0 (none) to 3 (all the time/very much). Question 2: 0 (happy), 1 (slightly fretful), 2 (very fretful),3 (always crying). Question 3: 0 (0-15 minutes), 1 (15 minutes-1 hour), 2 (1-2 hours),3 (\>2 hours).Question 4: 0 (\<1 hour), 1 (1-2 hours), 2 (3-4 hours),3 (\>=5 hours). IDQOL total score is the sum of the score of each question of LQI, ranges from 0 (no impact) to 30 (maximum impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24
A modified version of the UAS (mUAS) was used for the smaller body surface area of child and adolescent participants. The mUAS was derived from the sum of daily hives severity score (HSS) (ranging from 0 to 3 \[0 = absent; 1 = mild {1 to \<10 wheals/24 hours}; 2 = moderate: {10 to 30 wheals/24 hours}; and 3 = intense: {\>30 wheals/24 hours or large confluent areas of wheals}\]) and daily itch severity score (ISS) (ranging from 0 = none to 3 = intense). Daily mUAS total scores range from 0 to 6 (0 to 3 for ISS and 0 to 3 for HSS). Daily mUAS scores were summed over 7-day period to create total score ranging from 0 (no urticaria) to 42 (severe urticaria). Completion of mUAS7 was done by the child or parent(s)/caregiver(s)/legal guardian(s) for participants aged \>=4 years and by parent(s)/caregiver(s) for participants aged \<4 years. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
Time frame: Baseline (Day -7 to Day 1) and Week 24
Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
Time frame: Baseline (Day -7 to Day 1) and Week 24
Change From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24
The HSS7 score is the sum of daily HSS ranging from ranging from 0 to 3 (0 = absent; 1 = mild \[1 to \<10 wheals/24 hours\]; 2 = moderate \[10 to 30 wheals/24 hours\]; and 3 = intense: \[\>30 wheals/24 hours or large confluent areas of wheals\]) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
Time frame: Baseline (Day -7 to Day 1) and Week 24
This study was conducted at 10 sites in Canada, Japan and the United States. A total of 23 participants were screened from 25-Aug-2022 to 02-May-2024 of which 8 were screen failures mainly due to not meeting eligibility criteria.
| Milestone | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Started | 1 | 4 | 2 | 8 |
| Completed | 1 | 3 | 2 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Blood samples were collected at specified timepoints to obtain dupilumab concentration.
| nanogram/milliliter | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Week 12 | 67700 | 105000 | 45800 ± 12400 | 91600 ± 23000 |
| Week 24 | 116000 | 141000 ± 30100 | 51100 ± 20100 | 78500 ± 31600 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
| Participants | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| TEAEs | 1 | 2 | 2 | 7 |
| TESAEs | 0 | 0 | 0 | 0 |
Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.
| Participants | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Dupilumab | 0 | 0 | 0 | 0 |
The C-DLQI assesses impact of skin disease on children's health-related quality of life (HRQoL) over the previous week, contains 10 questions related to symptoms feelings associated with disease, impact of disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease. All questions were scored on 4-point Likert scale:0 (not at all),1 (a little),2 (a lot),3 (very much). Total C-DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.
| score on a scale | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24 | -3.0 | -6.0 | -10.5 ± 3.5 | -7.3 ± 4.3 |
The IDQOL questionnaire is completed by child's caregiver/guardian with a recall period of 7 days;consists of 10 questions focusing on life quality index (LQI) scored on 4-point Likert scale. An additional question on dermatitis severity is scored on a 5-point Likert scale (0 \[none\] to 4 \[extremely severe\]); it is not considered for calculating total IDQOL. For LQI, score ranges are as follows: Questions 1, 5 to 10: 0 (none) to 3 (all the time/very much). Question 2: 0 (happy), 1 (slightly fretful), 2 (very fretful),3 (always crying). Question 3: 0 (0-15 minutes), 1 (15 minutes-1 hour), 2 (1-2 hours),3 (\>2 hours).Question 4: 0 (\<1 hour), 1 (1-2 hours), 2 (3-4 hours),3 (\>=5 hours). IDQOL total score is the sum of the score of each question of LQI, ranges from 0 (no impact) to 30 (maximum impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.
| score on a scale | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Change From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24 | — | -3.0 | — | — |
A modified version of the UAS (mUAS) was used for the smaller body surface area of child and adolescent participants. The mUAS was derived from the sum of daily hives severity score (HSS) (ranging from 0 to 3 \[0 = absent; 1 = mild {1 to \<10 wheals/24 hours}; 2 = moderate: {10 to 30 wheals/24 hours}; and 3 = intense: {\>30 wheals/24 hours or large confluent areas of wheals}\]) and daily itch severity score (ISS) (ranging from 0 = none to 3 = intense). Daily mUAS total scores range from 0 to 6 (0 to 3 for ISS and 0 to 3 for HSS). Daily mUAS scores were summed over 7-day period to create total score ranging from 0 (no urticaria) to 42 (severe urticaria). Completion of mUAS7 was done by the child or parent(s)/caregiver(s)/legal guardian(s) for participants aged \>=4 years and by parent(s)/caregiver(s) for participants aged \<4 years. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
| score on a scale | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Change From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24 | -8.0 | -21.4 ± 1.9 | -2.8 ± 1.8 | -7.8 ± 6.6 |
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
| score on a scale | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24 | -5.0 | -9.6 ± 3.7 | -1.6 ± 0.6 | -3.4 ± 3.2 |
The HSS7 score is the sum of daily HSS ranging from ranging from 0 to 3 (0 = absent; 1 = mild \[1 to \<10 wheals/24 hours\]; 2 = moderate \[10 to 30 wheals/24 hours\]; and 3 = intense: \[\>30 wheals/24 hours or large confluent areas of wheals\]) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.
| score on a scale | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| Change From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24 | -3.0 | -11.8 ± 1.8 | -1.2 ± 1.2 | -4.4 ± 3.6 |
Collected over From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab 200 mg Q4W | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dupilumab 300 mg Q4W | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Dupilumab 300 mg Q4W, 600 mg Loading Dose | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Dupilumab 200 mg Q2W, 400 mg Loading Dose | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/1 | 0/4 | 2/2 | 0/8 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 1/1 | 1/4 | 0/2 | 2/8 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/1 | 0/4 | 0/2 | 0/8 |
| Hand-Foot-And-Mouth DiseaseInfections and infestations | 0/1 | 0/4 | 1/2 | 0/8 |
| HordeolumInfections and infestations | 0/1 | 0/4 | 1/2 | 0/8 |
| InfluenzaInfections and infestations | 0/1 | 0/4 | 1/2 | 1/8 |
| Otitis MediaInfections and infestations | 0/1 | 0/4 | 1/2 | 0/8 |
| Rhinovirus InfectionInfections and infestations | 0/1 | 1/4 | 0/2 | 0/8 |
| Subcutaneous AbscessInfections and infestations | 0/1 | 1/4 | 0/2 | 0/8 |
| InsomniaPsychiatric disorders | 0/1 | 1/4 | 0/2 | 0/8 |
The safety population included all enrolled participants who took at least 1 dose of the study intervention, regardless of the amount of intervention administered.
| Age, Customized(Participants) | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose | Total |
|---|---|---|---|---|---|
| >=2 to <6 years | 0 | 4 | 0 | 0 | 4 |
| >=6 to <12 years | 1 | 0 | 2 | 8 | 11 |
| Sex: Female, Male(Participants) | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 6 | 11 |
| Male | 0 | 2 | 0 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Dupilumab 200 mg Q4W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q4W, 600 mg Loading Dose | Dupilumab 200 mg Q2W, 400 mg Loading Dose | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| White | 0 | 4 | 1 | 4 | 9 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2022 to primary completion in Nov 2024, 26 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 26 months is close to that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab